Synthesis and antimicrobial activity evaluation of pyrazole derivatives containing the imidazo[2,1-b][1,3,4]thiadiazole moiety

Arch Pharm (Weinheim). 2023 Aug;356(8):e2300110. doi: 10.1002/ardp.202300110. Epub 2023 Jun 16.

Abstract

Four series of novel pyrazole derivatives (compounds 17a-m, 18a-m, 19a-g, and 20a-g) were synthesized, and their antibacterial and antifungal activities were evaluated. Most of the target compounds (17a-m, 18k-m, and 19b-g) showed strong antifungal activity and high selectivity relative to both Gram-positive and Gram-negative bacteria. Among them, compounds 17l (minimum inhibitory concentration [MIC] = 0.25 µg/mL) and 17m (MIC = 0.25 µg/mL) showed the strongest antifungal activity, being 2- and 4-fold more active than the positive controls gatifloxacin and fluconazole, respectively. In particular, compound 17l showed little cytotoxicity against human LO2 cells and did not exhibit hemolysis at ultrahigh concentrations, as did the positive control compounds gatifloxacin and fluconazole. These results indicate that these compounds are valuable for further development as antifungal agents.

Keywords: antibacterial; antifungal; hemolysis; pyrazole; thiadiazole.

MeSH terms

  • Anti-Bacterial Agents* / pharmacology
  • Antifungal Agents / pharmacology
  • Fluconazole / pharmacology
  • Gatifloxacin
  • Gram-Negative Bacteria
  • Gram-Positive Bacteria
  • Humans
  • Microbial Sensitivity Tests
  • Pyrazoles / pharmacology
  • Structure-Activity Relationship
  • Thiadiazoles* / pharmacology

Substances

  • Anti-Bacterial Agents
  • Antifungal Agents
  • Gatifloxacin
  • Thiadiazoles
  • Fluconazole
  • Pyrazoles